Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
NPJ Breast Cancer
.
2022 Feb 3;8(1):17.
doi: 10.1038/s41523-022-00392-3.
Authors
Julia Foldi
1
,
Andrea Silber
1
,
Emily Reisenbichler
2
,
Kamaljeet Singh
2
,
Neal Fischbach
1
,
Justin Persico
1
,
Kerin Adelson
1
,
Anamika Katoch
1
,
Nina Horowitz
3
,
Donald Lannin
3
,
Anees Chagpar
3
,
Tristen Park
3
,
Michal Marczyk
1
4
,
Courtney Frederick
1
,
Trisha Burrello
1
,
Eiman Ibrahim
1
,
Tao Qing
1
,
Yalai Bai
2
,
Kim Blenman
1
,
David L Rimm
2
,
Lajos Pusztai
5
Affiliations
1
Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
2
Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
3
Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
4
Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland.
5
Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA. lajos.pusztai@yale.edu.
PMID:
35115541
PMCID:
PMC8814070
DOI:
10.1038/s41523-022-00392-3
No abstract available
Publication types
Published Erratum
Grants and funding
UL1 TR001863/TR/NCATS NIH HHS/United States